Mesa Laboratories, Inc. (NASDAQ:MLAB) Director John Bradley Schmieder Sells 1,571 Shares

Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Rating) Director John Bradley Schmieder sold 1,571 shares of the business’s stock in a transaction on Friday, January 13th. The shares were sold at an average price of $191.31, for a total value of $300,548.01. Following the completion of the sale, the director now owns 68,976 shares of the company’s stock, valued at $13,195,798.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

John Bradley Schmieder also recently made the following trade(s):

• On Friday, November 11th, John Bradley Schmieder sold 2,500 shares of Mesa Laboratories stock. The shares were sold at an average price of $175.45, for a total value of $438,625.00.

Mesa Laboratories Price Performance

Mesa Laboratories stock opened at $184.09 on Wednesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.13 and a current ratio of 2.80. Mesa Laboratories, Inc. has a 52 week low of $114.21 and a 52 week high of $303.84. The stock has a market capitalization of $982.49 million, a P/E ratio of -242.22 and a beta of 0.68. The stock has a fifty day moving average of $174.31 and a 200-day moving average of $170.56.

Mesa Laboratories (NASDAQ:MLAB – Get Rating) last posted its quarterly earnings results on Thursday, November 3rd. The medical instruments supplier reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $1.24. Mesa Laboratories had a positive return on equity of 6.71% and a negative net margin of 1.78%. The company had revenue of $58.75 million during the quarter, compared to analysts’ expectations of $53.24 million. On average, sell-side analysts expect that Mesa Laboratories, Inc. will post 6.52 earnings per share for the current fiscal year.

Mesa Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 15th. Stockholders of record on Tuesday, February 28th will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Monday, February 27th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.35%. Mesa Laboratories’s dividend payout ratio (DPR) is currently -84.21%.

Hedge Funds Weigh In On Mesa Laboratories

A number of institutional investors have recently modified their holdings of the business. State of New Jersey Common Pension Fund D acquired a new position in Mesa Laboratories in the 2nd quarter worth about $2,185,000. Exchange Traded Concepts LLC increased its holdings in Mesa Laboratories by 3.0% in the 2nd quarter. Exchange Traded Concepts LLC now owns 5,074 shares of the medical instruments supplier’s stock worth $1,035,000 after purchasing an additional 146 shares in the last quarter. Nisa Investment Advisors LLC acquired a new position in Mesa Laboratories in the 2nd quarter worth about $414,000. Envestnet Asset Management Inc. increased its holdings in Mesa Laboratories by 13.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 12,790 shares of the medical instruments supplier’s stock worth $2,608,000 after purchasing an additional 1,546 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. increased its holdings in Mesa Laboratories by 5.8% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 5,224 shares of the medical instruments supplier’s stock worth $736,000 after purchasing an additional 285 shares in the last quarter. Institutional investors and hedge funds own 93.00% of the company’s stock.

Analyst Ratings Changes

MLAB has been the subject of several analyst reports. Evercore ISI lifted their price objective on Mesa Laboratories to $166.00 in a report on Tuesday, November 15th. StockNews.com raised Mesa Laboratories from a “sell” rating to a “hold” rating in a report on Friday, January 13th.

Mesa Laboratories Company Profile

(Get Rating)

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries.